基于高分子材料的降眼压药物递送系统

Drug Delivery Systems Based on Polymer Materials for Lowering Intraocular Pressure

目前治疗青光眼降眼压药物面临着生物利用率低、给药不连续、患者依从性差及长期组织毒性等问题。为了更好地满足临床需要,材料工程化技术被逐渐用于新型降眼压药物递送系统的研发,其中有部分成果已经进入临床应用。基于前期工作及对新型眼部药物递送系统的理解,本文简要介绍了眼部生理结构和目前用药困境,简单归纳了可用于青光眼降眼压药物递送系统的高分子材料,系统总结了基于高分子材料研发的新型药物递送系统,并对其未来的发展进行了展望。

Glaucoma drug therapy for lowering intraocular pressure suffers from some deficiencies,such as low bioavailability,discontinuous drug action,poor patient compliance and long-term tissue toxicity.To meet clinical needs more effectively,materials engineering technologies are gradually used for the development of novel intraocular pressure lowering drug delivery systems(DDSs),and some have been commercialized in clinical treatments.However,there is still a significant gap between commercial products and clinical needs in terms of safety and treatment efficacy.Based on our previous work and understanding of glaucoma treatment and novel ocular DDSs,we herein systematically summarize the recent research results of novel DDSs in lowering intraocular pressure.Initially,the physiological structure of the eye and the difficulties of drug therapy are introduced,and then polymer materials used to develop drug delivery systems for intraocular antihypertensive therapy are summarized.New DDSs based on polymer materials,such as solid implants,gel-based DDSs and nanocarrier-based DDSs are reviewed.Furthermore,we briefly introduce the DDSs developed by our group for improving intraocular pressure.After simply analyzing the limitations of commercial ocular drug delivery systems in clinical applications,we prospect the future development of intraocular pressure lowering DDSs in the directions of more effective,more targeted and more intelligent DDSs.